An intragastric balloon is a temporary device placed inside the stomach to occupy space and support earlier fullness and reduced food intake. Balloon therapy is used together with a structured nutrition and behavior program; it is not a permanent implant and does not replace long-term weight-management habits.
FDA-approved example
ORBERA® is an FDA-approved intragastric balloon system for adults with BMI 30–40 kg/m² who have not achieved adequate results with more conservative weight-loss approaches. FDA labeling specifies use with a long-term supervised diet and behavior-modification program and a maximum placement period of six months.
Candidacy depends on the specific balloon system, BMI, prior gastrointestinal or bariatric procedures, medical conditions, medications, and ability to complete follow-up and device removal.
Nausea, vomiting, abdominal discomfort, cramping, or reflux are common early after placement while the stomach adapts. Patients typically follow a staged dietary plan and need ready access to their treatment team if symptoms become severe or persistent.
Balloon therapy is less invasive than surgery but is not risk-free. Risks can include significant nausea or vomiting, dehydration, gastric ulceration, balloon intolerance, deflation or migration, bowel obstruction, pancreatitis, gastric perforation, and other uncommon but serious complications. Patients should receive device-specific warning signs and emergency instructions.
For ORBERA, FDA labeling specifies a maximum placement period of six months. The balloon must be removed endoscopically. Long-term weight maintenance depends on the plan that continues after removal.
A balloon is temporary and occupies space inside the stomach. ESG uses endoscopic sutures to reshape the stomach and is not designed as a temporary space-occupying device. The appropriate option depends on goals, anatomy, BMI, expected weight loss, risk tolerance, and access.
Insurance coverage for intragastric balloon therapy varies and is often more limited than coverage for established bariatric surgery. Coverage and self-pay requirements should be confirmed before treatment.
No. Intragastric balloons are temporary and require removal according to the device-specific schedule.
Placement is generally performed endoscopically through the mouth rather than through abdominal incisions.
Deflation can occur and is an important device-specific risk. Patients should know the warning signs and follow-up requirements.
Weight regain can occur. Long-term nutrition, activity, behavioral support, and medical treatment when appropriate remain important.
Medication may be considered in selected patients, but combination strategies should be individualized.
This page is educational and does not replace individualized medical advice. Balloon systems differ in indications, duration, contraindications, risks, and availability. Device-specific FDA labeling should guide treatment.
Prepared using current U.S. FDA information for intragastric balloon systems, including ORBERA. FDA records list ORBERA for adults with BMI 30–40 kg/m² with a maximum placement period of six months.
